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catheter placement (ie, after peritonitis severe enough to
require peritoneal dialysis catheter removal); and 6, severe
rejection episodes in transplant recipients (who have lost
or not yet had AV access).
Long-term hemodialysis. Patients undergo long-term
hemodialysis for the following indications: 1, long-term
treatment of chronic renal failure; and 2, awaiting kidney
transplantation. 
CHARACTERIZATION SYSTEM AND NOMEN-
CLATURE
Many terms are used inconsistently to describe various
configurations of AV access. A component-based system is
recommended. This system is based on three essential cat-
egories to be included in describing each procedure: con-
duit, location, and configuration. Although the use of
additional modifiers is not precluded by this system, they
should be supplemental to the three essential components,
described subsequently.
Conduit. Autogenous is used to describe native vein,
whether it is in situ, transposed, or translocated. An auto-
genous AV access is an access created by a connection
between an artery and a vein whereby the vein serves as an
accessible conduit. Nonautogenous AV access is an access
created by connecting an artery to a vein with a graft.
CLASSIFICATION OF INDICATIONS FOR
ACCESS PLACEMENT
Outcomes from published arteriovenous hemodialysis
(AV) access experiences cannot be meaningfully compared
unless a subanalysis of the relative indications used is
included. Therefore, this is a recommended standard, and
the following classification is submitted for that purpose.
Temporary hemodialysis. Tunneled or nontunneled
hemodialysis catheters are commonly used to provide tem-
porary access in the following situations: 1, acute renal
failure; 2, overdose or intoxication; 3, urgent access in
patients with chronic renal failure without available
mature access; 4, temporary access until functionality of
AV access is restored or the access replaced; 5, as substi-
tute access in patients with peritoneal dialysis while their
abdomens are being “rested” before new peritoneal
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The incidence rate of treated end-stage renal disease in the United States is 180 per million and continues to rise at a
rate of 7.8% per year. Arteriovenous hemodialysis access (AV access) creation and maintenance are two of the most dif-
ficult issues associated with the management of patients on hemodialysis. The 1-year complication rate of a primary
prosthetic AV access for hemodialysis ranges from 33% to 99%. Various investigators report on patency and complica-
tions of AV access. However, it is rather difficult to compare outcomes because of the wide variety of access materials,
configurations, locations, risk factors, and quality of inflow and outflow vessels. Although there have been reporting
standards for dialysis access endovascular interventions and for central venous access placement, standards regarding
surgical access placement and its revision are lacking. The “Dialysis Outcome Quality Initiative,” published by the
National Kidney Foundation, provides recommendations for optimal clinical practices aimed at improving dialysis out-
come and patient survival. This reporting standards document is not meant to be a “practice guidelines” or “best prac-
tices” document. Rather, the purpose of this document is to provide standardized definitions related to AV access
procedures and to recommend reporting standards for patency and complications, to be used by surgeons, nephrolo-
gists, and interventional radiologists, that will permit meaningful comparisons among AV access procedures. The terms,
definitions, and categories featured in this article have been approved by the Committee on Reporting Standards of the
Society for Vascular Surgery and the American Association for Vascular Surgery and should be observed in preparing
manuscripts on AV accesses for submission to the Journal of Vascular Surgery. (J Vasc Surg 2002;35:603-10.)
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Nonautogenous can be divided into prosthetic, such as
expanded polytetrafluoroethylene or Dacron, and
biograft, such as bovine heterograft or human umbilical
vein. Additional prosthetic descriptors, such as tapered,
ringed, or thin walled, may be used as indicated.
Location. The specific anatomic sites of origination
and termination of the AV access should be included in
this component. Arterial inflow site is reported first, fol-
lowed by a hyphen, and then the venous outflow site. In
instances in which such a descriptor may be ambiguous,
the addition of a broader anatomic reference should be
included. This is typically reported as the body region or
area where the access procedure is located and where can-
nulation will occur. Common examples include forearm
and upper arm. Less common examples include inguinal
and body wall. (Eg, a brachial-cephalic access should be
described as either a forearm brachial-cephalic or upper
arm brachial-cephalic access.)
Configuration. This component gives descriptive
information regarding the anastomotic connection and
course of the conduit. Initial descriptors include either
direct or indirect. Additional descriptors, such as trans-
posed, translocated, straight, or looped, may be used. A
direct access refers to a connection between native artery
and vein and includes end-to-side, side-to-side, and end-
to-end anastomoses. An indirect access is one in which
either an autogenous or prosthetic material is inserted
between the artery and vein to establish the connection.
Because all prosthetic access materials by definition are of
the indirect configuration, the descriptor indirect may be
omitted when a prosthetic access is described.
An access performed with a transposed vein is a trans-
position and is a subtype of the direct descriptor and may
be used in its place. It is used when the peripheral portion
of the vein is moved from its original position, typically
through a more superficial tunnel and connected to the
artery, and the more central portion remains intact in its
native location. The much less commonly used transloca-
tion access is a subtype of the indirect descriptor and may
be used in its place. It describes a vein that has been dis-
connected both proximally and distally and is inserted in a
position remote from its origin requiring anastomoses to
both the arterial and venous segments of the access.
Looped and straight refer to the course of the conduit. It
should be noted that their inclusion is not essential when
the configuration can be inferred from the anatomic
descriptors. Tables I to IV outline the newly recom-
mended nomenclature.
Categories for catheters
Catheters have traditionally been referred to as either
temporary or permanent. These descriptors are often inac-
curate, and catheters intended for temporary access and
designed to be placed percutaneously without the need for
a subcutaneous tunnel should be described as nontun-
neled catheters followed by their vein of insertion.
Catheters intended for prolonged usage and placed
through a subcutaneous tunnel should be described as
tunneled followed by their vein of insertion. Although dis-
couraged, catheters can also be referred to as cuffed and
noncuffed to indicate whether they are equipped with a
subcutaneous cuff to promote tissue ingrowth and further
fixation of the catheter. Examples of possible dialysis
catheter descriptors are: tunneled right internal jugular
vein hemodialysis catheter, nontunneled left internal jugu-
lar vein hemodialysis catheter, tunneled right femoral vein
hemodialysis catheter, and tunneled left femoral vein
hemodialysis catheter.
PREOPERATIVE EVALUATION
Grading of factors that modify outcome
It is difficult to compare outcomes among reported
studies if factors that affect the results of particular access
procedures are not identified and graded. A suggested
grading scheme is presented in Table V. The grading
scheme is organized into systemic factors, local limb fac-
tors, and miscellaneous factors that may affect outcome.
The timeliness of placement and the material of the AV
access are important factors in providing hemodialysis.
Other factors that may affect and modify outcomes are
Table I. Forearm access procedures
Recommended nomenclature Traditional nomenclature
Autogenous
Autogenous posterior radial branch-cephalic direct access Snuff box fistula
Autogenous radial-cephalic direct wrist access Brescia-Cimino arteriovenous fistula
Autogenous ulnar-basilic forearm transposition Superficial venous transposition in the forearm, basilic vein 
to ulnar artery
Autogenous radial-cephalic forearm transposition Superficial venous transposition in the forearm, cephalic vein
to radial artery
Autogenous brachial-cephalic forearm looped transposition Superficial venous transposition in the forearm, cephalic vein
to brachial artery, looped
Autogenous radial-brachial indirect saphenous vein translocation Greater saphenous vein reversed and translocated radial 
artery to brachial vein
Prosthetic
Prosthetic brachial-antecubital forearm loop access ePTFE forearm loop graft
Prosthetic radial-median cubital forearm straight access ePTFE forearm straight graft
ePTFE, Expanded polytetrafluoroethylene.
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also outlined in Table V, and a grading system is recom-
mended for each.
Grading of anatomic factors that affect access patency
The anatomy of the arterial and venous circuits
involved in the placement of the AV access should be eval-
uated and findings reported so results can be evaluated in
a meaningful way. If clinical examination results are clearly
satisfactory, the access is placed. If not, noninvasive and
even invasive methods are used for evaluation.1,2 The fol-
lowing discussion identifies recommended methods for
grading findings of diagnostic evaluations for reporting
purposes.
Arterial inflow
Pulse examination. The axillary, brachial, radial, and
ulnar artery pulses are carefully palpated in both upper
extremities, and, when indicated, the femoral, popliteal, and
pedal arteries are palpated. We propose the following scor-
ing system: healthy pulse will be given a score of “0,” a
diminished pulse a score of “1,” and an absent pulse a score
of “2.” Clearly, a subcritical inflow lesion may be missed in
the preoperative pulse evaluation. One should suspect this
condition in patients who have had radiation therapy in the
vicinity of the axillary and brachial arteries and in patients
with multiple arterial occlusive lesions elsewhere.3
Segmental blood pressures. The difference in blood
pressure between the two extremities should be reported
and graded with the following scoring system: no differ-
ence will be given a score of “0,” a less than 10 mm Hg
difference a score of “1,” a difference between 10 and 20
mm Hg a score of “2,” and a difference of more than 20
mm Hg a score of “3.”
The Allen Test. The Allen Test4 is used to assess the
arterial competence of the palmar arch. Definitions of pos-
itive and negative Allen test results for each of the radial
and ulnar arteries are seen in the following description.
Compression of both radial and ulnar arteries is used while
the fist is clenched, then the fist is relaxed revealing
blanched palm. For the test results to be defined as posi-
tive for radial artery insufficiency, the blanching continues
5 seconds or more after release of radial artery compres-
sion while the ulnar artery compression continues. For the
test results to be defined as positive for ulnar artery insuf-
ficiency, blanching continues 5 seconds or more after
release of ulnar artery compression while the radial artery
compression continues.
Arterial and arteriovenous access measurements
with duplex ultrasound scanning. Duplex ultrasound
scan can determine the diameter of the artery. It has been
found that a preoperative radial artery diameter of less
than 1.6 mm resulted in failure of the radial-cephalic wrist
autogenous AV access.5 In addition, duplex ultrasound
scan can determine the velocity of blood flow in the AV
access after construction. This measurement has been
found to influence the long-term patency of the radial-
cephalic wrist autogenous AV access. A flow rate of greater
than 400 mL/min two weeks after access creation indi-
cated a successful access, whereas a flow rate of less than
250 mL/min two weeks afterward indicated an access des-
tined to fail.5
Conventional arteriography or magnetic resonance
angiography. Contrast arteriography remains the gold stan-
dard for the evaluation of a suspected inflow stenosis or
occlusion. When in doubt regarding the adequacy of the
donor artery or the runoff, it is advisable to obtain an arte-
riogram that shows the entire arterial system from the origin
of the subclavian to the distal branches. Magnetic resonance
angiography can also be used for the same purpose.
Venous outflow
Clinical examination. Gross assessment of the super-
ficial veins may be accomplished by first placing the arm in
a dependent position and waiting for the veins to fill up
naturally. Visual enhancement of the superficial veins can
be provoked by placing a tourniquet on the upper arm
while the patient clenches and releases the ipsilateral hand
several times. On natural or provoked vein distention, one
should measure the outside diameter of the vein. The fol-
lowing grading system is used to score the vein diameter:
a vein that is more than 5 mm is scored as “0,” 4 to 5 mm
scored as “1,” 3 to 4 mm scored as “2,” and less than 3
mm scored as “3.”
Duplex ultrasound scanning in the assessment of
the venous circuit.
Superficial veins. The adequacy of the superficial veins
can be determined with duplex ultrasound scan.
Examinations are performed with a tourniquet placed on
the patient’s mid forearm, followed by placement of the
tourniquet on the upper arm. The basilic and cephalic veins
Table II. Upper arm access procedures
Recommended nomenclature Traditional nomenclature
Autogenous
Autogenous brachial-cephalic upper arm direct access Cephalic vein to brachial artery
Autogenous brachial-basilic upper arm transposition Basilic vein transposition
Autogenous brachial-axillary indirect greater saphenous Greater saphenous vein reversed and translocated brachial 
vein translocation artery to axillary vein
Prosthetic
Prosthetic brachial-axillary access Brachial-axillary bridging graft
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are imaged with the highest frequency available (10 to 12
MHz) to ensure an acceptable B-mode imaging. Details of
the venous lumen, such as webs, can be visualized and
should be noted if present. On the basis of its lumen, a vein
will be scored as follows: healthy lumen and wall scored as
“0,” the presence of webs or sclerosis with fixed stenosis
scored as “1,” and a vein that is occluded is scored as “2.”
In addition, the length of usable vein should be measured,
and the length is scored as follows: a vein length of more
than 14 cm will be given the score of “0,” 7 to 14 cm a
score of “1,” and less than 7 cm a score of “2.”
Deep veins. Duplex scanning of the deep venous system
for evaluation of stenosis or occlusion may be performed.
The quality of the deep vein lumen is scored the same way
as the superficial vein is scored.
Contrast venography. Venography may also be indi-
cated to determine the patency and adequacy of the super-
ficial and deep venous systems, including central veins.
GRADING OF COMPLICATIONS
Characteristics and grading of complications are
detailed in Table VI. The following are descriptions and
clarifications of some unusual complications so that iden-
tification is appropriately made.
Steal syndrome
All AV accesses divert or “steal” blood from the distal
circulation.6 A clinical syndrome resulting from this loss of
distal circulation occurs when the various local compen-
satory mechanisms fail. This creates a zone of arterial
insufficiency in the tissues distal to the fistula with all the
usual clinical manifestations of vascular insufficiency: pain,
ischemic neuropathy, ulceration, and gangrene.
Venous hypertension
Venous hypertension invariably occurs with the arte-
rialization of the venous system. Clinical problems may
be manifested with severe degrees of venous hyperten-
sion.7
Neuropathy
Neuropathy in the patient for hemodialysis with a fis-
tula should always raise the suspicion of underlying
ischemia as the result of a steal syndrome. It is by far the
most common cause of a unilateral neuropathy in these
patients. Only when this diagnosis has been carefully
excluded should other causes be considered. These
include uremic neuropathy, diabetic neuropathy, carpal
tunnel syndrome, and other compartment syndromes,
such as the cubital or ulnar nerve compression syndrome.8
PATENCY ASSESSMENT
Valid comparisons on patency can be made only if
patency is defined in a way that can be universally used by
all specialties in a consistent manner. Before defining the
various types of patency, there are several important issues
to be considered:
Postintervention patency. To have definitions of
patency that are valid and complete, it becomes apparent
that not only should patency from the time of initial access
placement be defined but also the patency of the subse-
quent interventions. A radiologist or a surgeon who is
interested in comparing the ability of different methods in
maintaining or reestablishing patency of an access should
be able to measure and evaluate interval patency since that
intervention, not having to worry about the overall (life-
span) patency of an access.
Functionality. Successful hemodialysis is reliant on the
functionality of AV access. The word “functional” can be
added to qualify the word “patency.” Thus, “primary access
patency” can be modified to “primary access functional
patency” to emphasize the functionality of the access and its
continuous use for successful hemodialysis during its indi-
cated patency. An access is said to be “functional” when it is
Table III. Lower extremity access procedures
Recommended nomenclature Traditional nomenclature
Autogenous
Autogenous femoral–greater saphenous looped access Greater saphenous vein end-to-side to femoral artery fistula
transposition
Prosthetic
Prosthetic femoral-femoral looped inguinal access Femoral artery to femoral vein looped ePTFE graft
ePTFE, Expanded polytetrafluoroethylene.
Table IV. Body wall access procedures
Recommended nomenclature Traditional nomenclature
Prosthetic axillary-axillary chest access Collar graft or axillary artery to axillary vein with ePTFE graft
Prosthetic axillary-axillary chest loop access Axillary artery to ipsilateral axillary vein loop with ePTFE graft
Prosthetic axillary-internal jugular chest loop access Axillary artery to ipsilateral internal jugular ePTFE graft
Prosthetic femoral-femoral suprainguinal access Femoral artery to contralateral femoral vein ePTFE graft
Prosthetic axillary-femoral body wall access Axillary artery to femoral vein ePTFE graft
ePTFE, Expanded polytetrafluoroethylene.
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able to deliver a flow rate of 350 to 400 mL/min without
access recirculation to maintain a treatment time less than 4
hours.9 A nonfunctional AV access is an access that is not
being successfully used for hemodialysis whether it is patent
or not. However, a failing AV access is an access that is
patent, not thrombosed, but in which thrombosis and fail-
ure seems imminent because of hemodynamic impairments. 
Intent to treat.10 It is not uncommon for authors to
acknowledge an initial failure rate for a procedure but then
exclude these failures from the final calculation of cumula-
tive patency rates. Although information is not withheld,
the practice is deceiving. For example, if 25% of a particu-
lar intervention initially failed but 80% of those successful
were still patent after a given time period, only 60% of
those initially treated will have benefitted. This “intent to
treat” rule may occasionally seem too strict, as in a patient
in whom there is inability to gain percutaneous access for
an endovascular procedure or in a patient in whom a
planned outflow revision with patch angioplasty is not fea-
sible, and instead a new access is placed. However, to arbi-
trarily allow such “reasonable” variances creates more
problems than it solves, and therefore it is advised that the
“intent to treat” rule be used in all reports dealing with
patency of AV access.
Revision versus loss of arteriovenous access.
Revision of an AV access may require segmental replace-
Table V. Grading of factors that affect outcome
Systemic factors
Diabetes 0 None
1 Adult onset, controlled with diet of oral agents
2 Adult onset, controlled with insulin
3 Juvenile onset
Hypertension 0 None (diastolic, <90 mm Hg)
1 Controlled, with single drug
2 Controlled, with two drugs
3 Controlled, with three drugs or more, or uncontrolled
Tobacco use 0 None, or none for last 10 years
1 None current, but smoked in last 10 years
2 Current (includes abstinence less than 1 year), <1 pack/day
3 Current, >1 pack/day
HIV 0 None
1 HIV, no current infection, but with CD count > 200
2 HIV, no current infection, but with CD count < 200
3 HIV, with current infection
IVDA 0 None
1 Past history, none currently
2 Current history, can have autogenous AV access
3 Current history, no possibility of autogenous AV access
Limb factors
Venous outflow track 0 No stenosis
1 Stenosis, <50% in diameter
2 Stenosis, >50% in diameter
3 Occlusion
Previous procedures same limb 0 No prior procedures
1 One prior procedure
2 Two prior procedures
3 Three or more prior procedures
Miscellaneous factors
Timeliness of referral 0 Referred 3 months before need for dialysis or creatinine level <4
mg/dL
1 Referred 1 month before need for dialysis
2 Referred when dialysis was imminent and could be managed 
with nontunneled catheter until access was ready for use
3 Referred when dialysis was imminent and needed tunneled 
catheter until access was ready for use
Choice of access location and conduit material 0 Placement of upper extremity autogenous AV access
1 Placement of upper extremity non-autogenous AV access
2 Placement of lower extremity autogenous AV access
3 Placement of lower extremity non-autogenous AV access
Choice of access site 0 Nondominant upper extremity
1 Dominant upper extremity
2 Lower extremity
3 Body wall
IVDA, Intravenous drug abuse; AV, arteriovenous.
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Table VI. Grading severity of arteriovenous-access complications
Complication Severity
Local access complications
Bleeding 0, None
Early, postoperative 1, Resolves without treatment
Prolonged bleeding from needle puncture sites 2, Medical therapy needed to correct coagulation abnormality
3, Intervention needed
Infection 0, None
Early (<30 days)/late (>30 days) 1, Resolved with antibiotic treatment
Culture: positive/negative 2, Loss of AV access because of ligation, removal, and possible
Site of infection: anastomosis/mid-AV access/runoff vein bypass
3, Loss of limb
Noninfectious fluid collections 0, None
Hematoma 1, Observed, resolved
Seroma 2, Aspirated, surgical drainage
Lymphocoele 3, Loss of AV access
Anastomotic complications 0, None
Hemorrhage: external bleeding/hematoma 1, Observed
Pseudoaneurysm: mechanical/infectious 2, Aspirated, surgical drainage, or correction maintaining AV 
Stenosis with intimal hyperplasia: venous anastomosis access functionality
3, Loss of AV access
Mid-AV access/runoff vein complications 0, None
Dilation/aneurysm 1, Observed, no treatment needed
Pseudoaneurysm at needle stick site 2, Local treatment: interventional/surgical revision
Mid-AV access stenosis 3, Loss of AV access
Access thrombosis 0, None
Early (<30 days)/late (>30 days) 1, Clot removal
Cause found (technical, anastomotic intimal 2, Revision with or without clot removal
hyperplasia, coagulation disorders) 3, Loss of AV access
Cause not found
AV access malfunction 0, Functional AV access
Insufficient inflow 1, Not corrected
Insufficient runoff 2, Required revision
Inability to puncture: too small/too deep 3, Loss of AV access
Remote complications
Steal syndrome 0, None
Healthy vasculature (anastomosis/runoff vessel too large) 1, Mild (cool extremity with few symptoms but demonstrable
Abnormal vasculature by flow augmentation with fistula occlusion), no treatment 
Inflow obstruction needed
Decreased collateral flow (eg, occluded ulnar artery with 2, Moderate (intermittent ischemia only during dialysis/
cephaloradial direct access) claudication), intervention sometimes needed
Distal arterial occlusive disease 3, Severe (ischemic pain at rest/tissue loss), intervention 
mandatory
Venous hypertension 0, None
Valvular incompetence with retrograde flow 1, Mild (minimal symptoms/discoloration/minimal extremity 
Central vein thrombosis: axillary/subclavian/internal swelling), no treatment needed
jugular/brachiocephalic/superior vena cava 2, Moderate (intermittent discomfort/severe swelling),
Runoff vein stenosis intervention usually needed
3, Severe (persistent discomfort with hyperpigmentation/
persistent swelling, severe or massive/venous ulceration), 
intervention mandatory
Neuropathy (excluding ischemia/steal) 0, None
Systemic: uremia (β2-microglobin amyloidosis)/diabetes 1, Mild, intermittent sensory changes (pain/paraesthesia/
Mechanical: entrapment or compartment syndromes numbness with sensory deficit)
(carpal tunnel/cubital or ulnar nerve compression) 2, Moderate, persistent sensory changes
3, Severe, sensory changes and progressive loss of motor func–
tion: movement/strength/muscle wasting
AV, Arteriovenous.
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ment. If the remaining segment can be used for dialysis
while the new segment is incorporating or maturing, the
access is considered revised and not replaced. However, if
the remaining segment is not adequate for continuous
dialysis and the patient needs a temporary catheter until
the newly placed segment matures, then the access is con-
sidered replaced.
Arteriovenous access removal or ligation because
of reasons other than thrombosis. If an AV access is
removed, ligated, or abandoned because of reasons other
than thrombosis (ie, infection, steal, venous hypertension,
or successful transplantation), then access functionality is
considered to have ceased, and patency is calculated as
continuing up to the time of permanent cessation of dial-
ysis using the access.
Time of measurement of patency. The time of mea-
surement of patency is the point in time when observation
or censoring of an access is performed.
Definitions of arteriovenous access patency
Primary patency. This is the interval from the time of
access placement until any intervention designed to main-
tain or reestablish patency, access thrombosis, or the time
of measurement of patency.
Assisted primary patency. This is the interval from
the time of access placement until access thrombosis or the
time of measurement of patency, including intervening
manipulations (surgical or endovascular interventions)
designed to maintain the functionality of a patent access
(number of interventions can be represented numerically
in between brackets after the actual patency of an access;
ie, assisted primary patency of 18 months [2]. This indi-
cates that the access has been functional for 18 months but
needed two interventions to maintain its functionality).
Secondary patency. This is the interval from the time
of access placement until access abandonment, thrombosis,
or the time of patency measurement including intervening
manipulations (surgical or endovascular interventions)
designed to reestablish functionality in thrombosed access.
Definitions of postintervention patency
Before defining postintervention patencies, we will
define and describe various interventions. An intervention
is any surgical or endovascular manipulation of the access
to maintain or reestablish its functionality. Although the
following list may change with the addition of new meth-
ods and technologies, such interventions can be divided
into surgical and endovascular.
Surgical interventions. A, Thrombectomy: surgical
removal of thrombus from the AV access; B, outflow patch
angioplasty: surgical revision of the venous outflow steno-
sis with a prosthetic or autogenous patch to enlarge a
stenosed outflow anastomosis; C, primary repair: a stenotic
area is resected and an end-to-end anastomosis is per-
formed; and D, segmental access replacement: this can be
one of four types: 1, venous outflow: surgical replacement
of the distal segment of the access to bypass an outflow
venous stenosis; 2, mid-access: surgical replacement of seg-
ment of the access not inclusive of its inflow or outflow
anastomoses; 3, arterial inflow: surgical replacement of the
proximal segment of the access to bypass an inflow arterial
stenosis to a different (usually more proximal) arterial
inflow; and 4, any combination of the previous can be used
such as venous outflow and mid-access replacement.
Endovascular interventions. A, Balloon angioplasty:
intraluminal balloon dilatation; B, stent deployment:
placement of a self-expanding or balloon expandable stent;
C, pharmacologic thrombolysis: catheter-directed infusion
of thrombolytic agents; D, mechanical thrombolysis and
thrombectomy: fragmentation, maceration, or mobiliza-
tion of thrombus by mechanical means or devices; and E,
pharmacomechanical thrombolysis: catheter-directed
administration of an agent that results in pharmacologic
thrombolysis accompanied by mechanical disruption of
thrombus by fragmentation, maceration, or mobilization.
Definitions of postintervention patency. The fol-
lowing definitions of postintervention patencies differ
slightly but are consistent with those published by the
Society for Cardiovascular and Interventional Radiology
(SCVIR).11 Of note, the SCVIR document applies only to
percutaneous endovascular manipulations. This docu-
ment’s definition of intervention encompasses all surgical
and endovascular manipulations.
Postintervention primary patency. This is the interval from
the time of any surgical or endovascular intervention until
thrombosis or the time of measurement of patency.
Postintervention assisted primary patency. This is the interval
from the time of intervention until first access thrombosis
or the time of patency measurement, including all inter-
vening similar manipulations (surgical or endovascular
interventions) designed to maintain the functionality of
the access. Of note, patency ends for a particular interven-
tion if another method is used to maintain patency. For
example, if a venous anastomotic lesion is dilated and
recurs and a surgical jump graft is performed, the assisted
primary patency of the balloon dilatation procedure has
ended (the number of interventions can be represented
numerically in between brackets after the actual patency of
an access; ie, assisted postintervention primary patency of 6
months [1]. This indicates that this access has an uninter-
rupted postintervention patency of 6 months but needed
one similar reintervention to maintain its functionality).
Postintervention secondary patency. This is the interval
from the time of intervention until access abandonment or
the time of patency measurement, including similar inter-
vening manipulations (surgical or endovascular interven-
tions) designed to reestablish functionality in thrombosed
access. The same definition is described as “postinterven-
tion access patency” in the SCVIR document.11
Definitions of catheter patency
It is important to distinguish catheter patency from
the more important concept of catheter site patency
because exchange for a new catheter over a wire would
end catheter patency but maintain site patency. This con-
cept has been identified previously, and we use it in a mod-
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ified form for conformity because the original document
emphasized endovascular interventions.12 In addition, we
introduce the concept of access vein survival to account for
availability of a certain vein (internal jugular, femoral) for
future access. We propose the following definitions.
Primary catheter site patency. This is the interval
from time of placement of the catheter until first interven-
tion, catheter malfunction, completion of therapy, and
catheter site abandonment or time of measurement of
patency.
Assisted primary catheter site patency. This is the
interval from time of placement until catheter malfunc-
tion, completion of therapy, and catheter site abandon-
ment or time of measurement of patency including
intervening manipulations (endovascular or surgical inter-
ventions) aiming to restore functionality of the catheter
without the need for its replacement (number of manipula-
tions can be represented numerically in between brackets
after the actual patency of a catheter; ie, assisted primary
catheter site patency of 2 months [2]. This indicates that
this catheter has an assisted primary catheter site patency
of 2 months but needed two interventions to restore its
functionality).
Secondary catheter site patency. This is the interval
from time of placement until catheter site abandonment,
completion of therapy, or time of measurement of patency
including catheter replacements (exchanges) provided the
access site is maintained. The number of catheter replace-
ments while maintaining the same site should be indicated
(number of manipulations can be represented numerically
in between brackets after the actual patency of a catheter;
ie, secondary patency of 2 months [2]. This indicates that
this site has a secondary patency of 2 months but needed
two catheter exchanges maintaining the original site).
Access vein survival
The concept of access vein patency is an important one
because a given vein can be used repeatedly throughout
the patient’s life on hemodialysis. Access vein survival is
defined as the period from the time point when a vein
(internal jugular, femoral, etc) was first used for access
until the vein is no longer usable for that purpose.
Estimating patency rates
Life table (LT) method13,14 and Kaplan-Meier (KM)
survival curves15 are acceptable methods to estimate
patency. In figures, the numbers of patients at risk at the
start of each interval (periodically for the KM) must be
included and the standard error for each estimate of
patency must be displayed with bars. When the standard
error of the patency rate estimate exceeds 10%, the curve
either should not be drawn or should be represented with
a dotted line as a means of indicating lack of reliability of
the estimate. Comparisons of patency curves should be
performed with the log-rank test of significance.16
Complete LT and KM data should be submitted as an
appendix with each report, to allow the validity of the data
to be evaluated.
Separate LTs should be provided for each type of
operative procedure. When pertinent, additional LT or
KM plots should be reported for major risk or treatment
factors that appear to affect patency. In some instances,
interdependence of variables will limit the confidence with
which conclusions may be drawn from this subgrouping of
data. In this situation, it is often appropriate to apply mul-
tivariate analysis with the Cox hazard regression analysis.17
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